Insider Trades
Kiniksa CEO Sanj Patel Plans To Sell 553,794 Shares Worth $51.6 Million
The planned sale follows a raised Arcalyst sales forecast and a 136.5% run in the stock this year.
KNSA
Kiniksa Pharmaceuticals International (KNSA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Kiniksa Stock Soars 22%, Adding $1.3 Billion, After Raising Its Arcalyst Forecast
The drugmaker's shares hit a 52-week high after third-quarter profit climbed and management lifted its full-year Arcalyst outlook.
SEC Filings
Kiniksa's Semi-Finished Drug Stock Hits $76.2 Million As Samsung Takes Over Manufacturing
Total ARCALYST inventory reached $112.7 million at September 30, up from $59.9 million at year-end, as sales climbed.
Earnings
Kiniksa CEO On Deals With Cash Piling Up: 'The Bar Is Exceedingly High'
The drugmaker ended the third quarter with $568.8 million in cash and says it leans on Arcalyst and its own pipeline.
Earnings
Kiniksa Sets Second-Half 2027 Data Date For Monthly Heart Drug, Eyes 2028-2029 Launch
Arcalyst is on track for over $1 billion in 2026 sales and is paying for the pipeline, management said.
Earnings
Kiniksa Raises Arcalyst Sales Forecast To $1.045 Billion-$1.050 Billion As Quarterly Profit Climbs
Net income rose to $47.3 million in the third quarter as Arcalyst revenue grew about 58%, and a late-stage KPL-387 readout is expected in 2027.
SEC Filings
Kiniksa Names Operating Chief Ross Moat President, Lifts His Salary To $700,000
The drugmaker's board committee gave Moat the added title on Saturday, with a higher salary and bonus target starting in January.